

Mouse Anti-HPV 16 [CAMVIR-1]: MC0801, MC0801RTU7

Intended Use: For Research Use Only

Description: The antibody reacts with a 56 kDa protein in cells infected with L1-vaccinia virus, the protein being present in a predominantly nuclear location. The antibody reacts very strongly with biopsy specimens containing HPV-16 or -33; very weak reactions were occasionally observed with biopsy specimens or smears containing HPV-6 or HPV-11. Cross-reacts with HPV37.L1 is a major capsid protein of type 16 human papilloma virus. Infection with specific types of HPV has been associated with an increased risk of developing cervical neoplasia. HPV types 6 and 11 have been associated with relatively benign diseases such as genital warts but types 16 and 18 are strongly associated with cervical, vaginal, and vulvar malignancies.

Specifications:

Clone: CAMVIR-1
 Source: Mouse
 Isotype: IgG2a/k
 Reactivity: Human
 Localization: Virion, host nucleus
 Formulation: Antibody in PBS pH7.4, containing BSA, and $\leq 0.09\%$ sodium azide (NaN₃)
 Storage: Store at 2°- 8°C
 Applications: IHC, ELISA, ICC/IF, IP, WB
 Package:

Description	Catalog No.	Size
HPV 16 Concentrated	MC0801	1 ml
HPV 16 Prediluted	MC0801RTU7	7 ml

IHC Procedure*:

Positive Control Tissue: Cervical cancer
 Concentrated Dilution: 50-200
 Pretreatment: Citrate pH6.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C
 Incubation Time and Temp: 30-60 min @ RT
 Detection: Refer to the detection system manual

* Result should be confirmed by an established diagnostic procedure.



FFPE human cervix stained with anti-HPV16 using DAB

References:

1. Expression of P16 in high-risk human papillomavirus related lesions of the uterine cervix in a government hospital, Malaysia. Krishnappa P, et al. Diagn Pathol 9:202, 2014.
2. A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies. Day PM, et al. Clin Vaccine Immunol 19:1075-82, 2012.
3. Human papillomavirus-like particles vaccine efficiently produced in a non-fermentative system based on insect larva. Millán AF, et al. Protein Expr Purif 74:1-8, 2010.

Doc. 100-MC0801
Rev. A